592 related articles for article (PubMed ID: 18250251)
21. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
[TBL] [Abstract][Full Text] [Related]
22. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.
Ray LA; Hutchison KE
Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.
Arias AJ; Gelernter J; Gueorguieva R; Ralevski E; Petrakis IL
Am J Addict; 2014; 23(3):288-93. PubMed ID: 24724887
[TBL] [Abstract][Full Text] [Related]
24. Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.
O'Brien CP
Curr Psychiatry Rep; 2008 Oct; 10(5):375-6. PubMed ID: 18803909
[No Abstract] [Full Text] [Related]
25. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Weiss RD; O'malley SS; Hosking JD; Locastro JS; Swift R;
J Stud Alcohol Drugs; 2008 Nov; 69(6):878-84. PubMed ID: 18925346
[TBL] [Abstract][Full Text] [Related]
26. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
[TBL] [Abstract][Full Text] [Related]
27. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
28. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
[TBL] [Abstract][Full Text] [Related]
29. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
30. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.
Donovan DM; Anton RF; Miller WR; Longabaugh R; Hosking JD; Youngblood M;
J Stud Alcohol Drugs; 2008 Jan; 69(1):5-13. PubMed ID: 18080059
[TBL] [Abstract][Full Text] [Related]
31. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
32. OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.
Foulds JA; Ton K; Kennedy MA; Adamson SJ; Mulder RT; Sellman JD
Pharmacogenet Genomics; 2015 May; 25(5):270-3. PubMed ID: 25715171
[TBL] [Abstract][Full Text] [Related]
33. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
[TBL] [Abstract][Full Text] [Related]
34. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
Soyka M; Rösner S
Curr Drug Abuse Rev; 2008 Nov; 1(3):280-91. PubMed ID: 19630726
[TBL] [Abstract][Full Text] [Related]
35. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
[TBL] [Abstract][Full Text] [Related]
36. Relationship between medication adherence and treatment outcomes: the COMBINE study.
Zweben A; Pettinati HM; Weiss RD; Youngblood M; Cox CE; Mattson ME; Gorroochurn P; Ciraulo D
Alcohol Clin Exp Res; 2008 Sep; 32(9):1661-9. PubMed ID: 18616687
[TBL] [Abstract][Full Text] [Related]
37. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
DeSantis SM; Bandyopadhyay D; Baker NL; Randall PK; Anton RF; Prisciandaro JJ
Drug Alcohol Depend; 2013 Sep; 132(1-2):244-50. PubMed ID: 23566774
[TBL] [Abstract][Full Text] [Related]
38. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
39. Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
Subbaraman MS; Metrik J; Patterson D; Swift R
Addiction; 2017 Apr; 112(4):685-694. PubMed ID: 27865015
[TBL] [Abstract][Full Text] [Related]
40. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers.
van den Wildenberg E; Wiers RW; Dessers J; Janssen RG; Lambrichs EH; Smeets HJ; van Breukelen GJ
Alcohol Clin Exp Res; 2007 Jan; 31(1):1-10. PubMed ID: 17207095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
